References
- Albini E, Belluco G, Berton M, et al. (1999). In vitro antibacterial activity of thiamphenicol glycinate acetylcysteinate against respiratory pathogens. Arzneimittelforschung 49:533–7
- Chang Y, Choue R. (2013). Plasma pharmacokinetics and urinary excretion of isoflavones after ingestion of soy products with different aglycone/glucoside ratios in South Korean women. Nutr Res Pract 7:393–9
- Chen X, Yang B, Ni L, Wang G. (2006). Simultaneous analysis of thiamphenicol and its prodrug thiamphenicol glycinate in human plasma and urine by high performance liquid chromatography: application to pharmacokinetic study. J Pharm Biomed Anal 41:943–9
- Dettli L, Krishna G, Ferrari V, Della Bella D. (1974). Comparison of chloramphenicol and thiamphenicol metabolism. Postgrad Med J 50:17–22
- Drago L, De Vecchi E, Fassina MC, et al. (2000). Serum and lung levels of thiamphenicol after administration of its glycinate N-acetylcysteinate ester in experimentally infected guinea pigs. Int J Antimicrob Ag 13:301–3
- Ferrari V. (1984). Salient features of thiamphenicol: review of clinical pharmacokinetics and toxicity. Sex Transm Dis 11:336–9
- Johan Gabrielsson DW. (2007). Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 4th ed. Stockholm, Sweden: Swedish Pharmaceutical Press
- Kitamura T, Ando J, Ishihara R, et al. (1997). Lack of carcinogenicity of thiamphenicol in F344 rats. Food Chem Toxicol 35:1075–80
- Mestorino N, Landoni MF, Alt M, Errecalde JO. (1993). The pharmacokinetics of thiamphenicol in lactating cows. Vet Res Commun 17:295–303
- National Institute on Alcohol Abuse and Alcoholism. (2009). How to screen for heavy drinking. Available from: http://pubs.niaaa.nih.gov/publications/Practitioner/PocketGuide/pocket_guide5.htm [last accessed 5 Mar 2014]
- Qiu Z, Li N, Wang X, et al. (2013). Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs. J Pharm Sci 102:741–9
- Raymond J, Boutros N, Bergeret M. (2004). Role of thiamphenicol in the treatment of community-acquired lung infections. Med Trop (Mars) 64:33–8
- Siboulet A, Bohbot JM, Lhuillier N, et al. (1984). “One-minute treatment” with thiamphenicol in 50,000 cases of gonorrhea: a 22-year study. Sex Transm Dis 11:391–5
- Sjoo F, El-Serafi I, Enestig J, et al. (2014). Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate. Clin Drug Invest 34:43–52
- Smith A. (2007). Bacterial resistance to antibiotics, 7th ed. Chichester, UK: Hugo and Russell’s Pharmaceutical Microbiology, 220–32
- Tanino T, Ogiso T, Iwaki M, et al. (1998). Enhancement of oral bioavailability of phenytoin by esterification, and in vitro hydrolytic characteristics of prodrugs. Int J Pharm 163:91–102
- Turton JA, Andrews CM, Havard AC, et al. (2002). Haemotoxicity of thiamphenicol in the BALB/c mouse and Wistar Hanover rat. Food Chem Toxicol 40:1849–61
- Turton JA, Havard AC, Robinson S, et al. (2000). An assessment of chloramphenicol and thiamphenicol in the induction of aplastic anaemia in the BALB/c mouse. Food Chem Toxicol 38:925–38
- Wright GD. (2005). Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv Drug Deliv Rev 57:1451–70
- World Health Organization. (2008). WHO report on the global tobacco epidemic. Available from: http://www.who.int/tobacco/mpower/mpower_report_full_2008.pdf [last accessed 5 Mar 2014]
- World Medical Association. (2008). Declaration of Helsinki (Version, 2008). Available from: http://www.wma.net/en/20activities/10ethics/10helsinki/ [last accessed 5 Mar 2014]
- Yang B, Lu Y, Zheng J, et al. (2011). Pharmacokinetics of the prodrug thiamphenicol glycinate and its active parent compound thiamphenicol in beagle dogs following intravenous administration. Xenobiotica 41:226–31